may 1st
Prime Editing: A Versatile Engineered CRISPR System
Targeting Efficiency and Flexibility: Observations of the enzyme's flexibility are drawn from targeting efficiency. Specifically, the site is targeted with the highest efficiency, and the site is targeted with identical efficiency. This indicates a high level of flexibility within the enzyme system.
Prime Editing (PE) Construction: Prime editing is characterized as an engineered version of the protein. Unlike standard CRISPR systems, it can mutate bases (similar to base editors) but also possesses the ability to make specific insertions or deletions at target sites.
The Two-Component System: Prime editing utilizes a complex two-component system: - Modified Cas9 Enzyme: This version of is fused to a reverse transcriptase (RT) and other potential modular attachments. - Prime Editing Guide RNA (pegRNA): The is more complex than a standard . It contains sequences for target recognition and an additional sequence at the end that serves as a template for the reverse transcriptase.
Scope and Therapeutic Impact of Prime Editing
Mutational Capability: The prime editor can perform: - All transition mutations (described in the transcript as purine to purine or purine to purine transitions). - All eight transversion point mutations (described as purine to purine or purine to purine transversions). - Sophisticated single-step engineering of insertions and deletions.
Impact on Human Genetic Disorders: Research into pathogenic human mutations indicates: - Approximately (exactly half) of known genetic disorders are point mutations (transitions or transversions), all of which are treatable via prime editing. - Including insertions and deletions, approximately two-thirds () of known human genetic mutations can be addressed. - Quantitative Scale: Out of the approximately known genetic disorders, roughly are directly treatable using prime editing methods.
The Prime Editing Mechanism and Optimization
Step-by-Step Mechanism: - Recognition: The nickase, fused to reverse transcriptase, recognizes the target via the . Identifying the target requires a Protospacer Adjacent Motif (). - Nicking: The enzyme creates a nick on the non-recognized DNA strand. - Extension: The reverse transcriptase uses the end generated by the nick to extend the DNA, using the RNA template provided by the . The intended edit (e.g., a three-base change) is incorporated during this synthesis. - Resolution: Once the prime editor dissociates, a "flap" of DNA remains. The cell's repair machinery must resolve this mismatch by chipping away at the old DNA flap and replacing it with the newly synthesized, edited sequence.
System Evolution: Since the initial description in , the system has been optimized through numerous permutations to improve functionality. A review published three years after the initial report () highlights variants designed for: - Improved nuclear and cellular localization. - Enhanced expression and nicking. - Better chromatin accessibility. - High activity in plants (where prime editing is used extensively).
Engineering the pegRNA and Enzyme Components
RNA Polymerase III (Pol III): Evolution of the system involves using for expression rather than . In eukaryotes, synthesizes non-messenger RNAs like and small nuclear RNAs (). It is highly effective at producing small RNA fragments that are not intended for translation.
pegRNA Protection: Three evolved versions of the have been developed to resist degradation by ribonucleases. These include modifications such as the AG quad complex to stabilize the small RNA molecules.
Clinical Timeline: Prime editing was described only seven years ago (relative to the lecture timeline) and is already entering clinical applications.
Managing Off-Target Effects and Protein Size
Off-Target Activity: does not always bind exclusively to its programmed target. There is a trade-off between binding strength and specificity. While high binding strength ensures activity, it also increases off-target effects.
Binding Affinity Engineering: To reduce off-target binding, researchers have mutated specific basic residues in the protein, such as Arginine () and Lysine (). By removing these positive charges, the enzyme's interaction with the negatively charged backbone is loosened, which effectively reduces off-target binding while maintaining sufficient catalytic activity for the intended site.
Protein Size Constraints: - Standard is a massive protein, weighing approximately . - Gene Therapy Vectors: Adeno-associated virus () vectors have a strict cargo limit of approximately . - Smaller versions of have been described for over ten years to address this limitation. - The "Operating System" Metaphor: Scientists are often hesitant to switch from the original to smaller variants because the original system has a massive established "tool set." Switching to a new protein is likened to moving to a new computer operating system that lacks the mature software and tools of the established one.
Delivery Mechanisms for CRISPR-Cas9
In Vitro Culture: Cells like stem cells or bone marrow can be grown in culture and transformed with a plasmid expressing the guide RNA and . This carries a risk of permanent alteration if the cell continues to produce these components.
Ribonucleoprotein (RNP) Injection: For a one-time edit, the preassembled protein and RNA can be injected directly. This works once and then degrades, leaving the cell modified but without permanent expression of editing tools.
mRNA Injection: Messenger RNA can be injected to be translated into protein within the cell.
Dual Delivery Strategy: A combined approach might use an to deliver the guide RNA and repair template alongside other delivery methods for the enzyme components.
Questions & Discussion
Question: Why would you want to use rather than ?
Answer: polymerase III is responsible for synthesizing non-messenger RNA, such as and small nuclear RNAs. It is better at making short, functional pieces of RNA that are not intended for translation, making it ideal for guide RNA production.
Question: Does reducing a binding site strength alter Cas9's ability to carry out its function at all?
Answer: Yes, there is likely a trade-off. By lowering affinity for , you may reduce overall activity, but as long as the catalytic activity remains functional at the target site, the trade-off is often acceptable to gain higher specificity.
Question: Can smaller versions of recognize the same length of targets as the standard ?
Answer: Generally, they recognize similar lengths, approximately bases. While it depends on the specific enzyme, the specificity length of around bases is standard across these systems.
Note on Logistics: A quiz is scheduled for Wednesday covering material up through CRISPR. A study guide will be posted. The quiz format offers "15 chances to get 10 points."